Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents on Novo Nordisk’s (NVO) diabetes and weight loss ...

Drugmaker Hikma is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents on Novo Nordisk’s blockbuster diabetes and weight loss drugs ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Drugmaker Hikma is in talks with partners across the world to prepare to sell a generic version of Ozempic ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...

The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hikma of an Abbreviated New Drug Application to the U.S. Food and ...

Hikma is introducing mercaptopurine oral suspension, in a 20mg/ml dose, which is the first generic of this product. Hikma was the first approved applicant with a Competitive Generic Therapy ...

Dividend amount and dividend per share are quoted in the currency of the stock selected. Please note that past performance is not a reliable indicator of future returns. Important Information Please ...

Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 billion (JT file) AMMAN — Hikma Pharmaceuticals PLC posted 'robust' financial results ...

Group core revenue up 10%, including contribution from Xellia acquisition (9% organic). Reported Group revenue up 9% Core revenue up in all three business segments – Injectables up 10%, Branded up 8% ...

Healthcare & Pharmaceuticalscategory· December 23, 2024 US FDA approves Hikma's generic version of Novo's diabetes drug Victoza The U.S. Food and Drug Administration on Monday approved Hikma ...